Peptide LibraryHuman study PLS-00230
Effect of Elamipretide on Left Ventricular Function in Subjects With Stable Heart Failure With Reduced Ejection Fraction
Version 1 · published November 8, 2026 · evidence through November 8, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.
Reports of this study
Every publication, registration and abstract describing this one study. Participants are counted once.
- Effect of Elamipretide on Left Ventricular Function in Subjects With Stable Heart Failure With Reduced Ejection Fractionregistry entry · NCT02788747 (COMPLETED, results posted, planned enrollment 71)
Design and participants
- Design
- Other design
- Population
- Adults with stable heart failure with reduced ejection fraction (per study title)
- Conditions
- Heart failure with reduced ejection fraction
- Planned enrollment (registry)
- 71
- Enrolled
- 71
- Randomized
- Not reported
- Completed follow-up
- Not reported
Intervention and comparator
What each group received. Related peptides, analogs and combinations are never treated as the compound itself.
- Elamipretide lower dose (intervention) · elamipretide · Elamipretide (also listed as MTP-131, Bendavia), lower of two registered dose levels · Not reported assigned
- Elamipretide higher dose (intervention) · elamipretide · Elamipretide (also listed as MTP-131, Bendavia), higher of two registered dose levels · Not reported assigned
- Placebo (comparator) · Placebo · placebo · Not reported assigned
What the authors reported
As stated in the sources. This is the authors’ account, not Peptide Library’s assessment.
Left ventricular function
unclear outcome · surrogate
- No results reported.
Adverse events
None reported. That is not evidence of safety, and how safety was monitored isn’t described.
Peptide Library’s assessment
An automated assessment, made by AI separately from the authors’ conclusions and not reviewed by a person. How risk of bias is assessed.
Limitations
- abstract only: Only registry fields are available. No results, methods detail or publication are included in the record, although results are flagged as posted.
- other: The registry fields in the record do not state whether allocation to the elamipretide and placebo arms was randomized or blinded.
- inappropriate endpoint: The outcome named in the title is left ventricular function, which is a surrogate imaging or physiological measure rather than a patient-felt outcome.
- inappropriate population: Participants had heart failure with reduced ejection fraction, not Barth syndrome or primary mitochondrial myopathy as in the claim questions.
No risk-of-bias assessment has been published for this study’s results.
Claims this study informs
- Improves function in Barth syndrome: not eligible (wrong population) for “Muscle strength, exercise capacity and fatigue”
- Improves exercise capacity in primary mitochondrial myopathy: not eligible (wrong population) for “Six-minute walk distance and fatigue”
- Is safe for human administration: not eligible (insufficient data) for “Adverse events, including injection-site reactions, and discontinuations”
Where each value comes from
- arms: NCT NCT02788747, registry (interventions) · extracted by AI (automated, not verified by a person)
- design: NCT NCT02788747, registry (phases, study_type, interventions) · extracted by AI (automated, not verified by a person)
- limitations: NCT NCT02788747, registry (has_results and absence of results fields) · extracted by AI (automated, not verified by a person)
- outcomes: NCT NCT02788747, title (study title) · extracted by AI (automated, not verified by a person)
- participants: NCT NCT02788747, registry (enrollment, enrollment_type) · extracted by AI (automated, not verified by a person)
- population: NCT NCT02788747, title (study title) · extracted by AI (automated, not verified by a person)
Version 1 · published November 8, 2026 · evidence through November 8, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.
These assessments describe published research. Records marked automated were produced by AI under the published methodology and have not been reviewed by a person; they can contain errors. None of this is medical advice, not a statement about any product’s safety for human use, and not a regulatory approval. Peptide Library’s vendor and partner relationships play no part in them (editorial independence).